Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. (NYSE: AVTR) is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. This news page aggregates company announcements, earnings updates and other disclosures so readers can follow how Avantor’s operations, portfolio and governance evolve over time.
Recent news releases describe Avantor’s participation in investor conferences, quarterly earnings reports, leadership and board appointments, and product and service developments. Examples include announcements about the timing of quarterly and full-year earnings releases and related conference calls, as well as participation in events such as the J.P. Morgan Healthcare Conference. These items provide context on how the company communicates with the investment community and presents its financial performance.
Product- and operations-focused news highlights areas such as bioprocessing, biomanufacturing and laboratory services. Avantor has reported the launch of a sterile sampling platform and PUPSIT assemblies for bioprocessing, the development of a biodegradable viral inactivation detergent recognized with an Edison Patent Award, and the expansion of its Centralized Service Center model with a facility serving the Greater Boston area. These updates illustrate how the company positions its tools and services within scientific and industrial workflows.
Corporate governance news includes the appointment of new directors and senior executives, such as additions to the Board of Directors and the creation of an Executive Vice President and Chief Operating Officer role. Together, these news items offer insight into Avantor’s strategic priorities, leadership changes and ongoing initiatives. Investors, analysts and industry participants can use this page to monitor company communications and official announcements over time.
Avantor (NYSE: AVTR) announced the pricing of an $800 million private offering of 3.875% Senior Notes due November 1, 2029. The offering is expected to close on October 26, 2021, and the funds will be used to finance the acquisition of the Masterflex bioprocessing business from Antylia Scientific, along with associated fees. The Notes are being offered to qualified institutional buyers in a private transaction under exemption provisions of the Securities Act. This press release contains forward-looking statements subject to risks and uncertainties.
Avantor (NYSE: AVTR) has announced a private offering of senior notes by its subsidiary, Avantor Funding, Inc., to finance the acquisition of Masterflex bioprocessing and related assets from Antylia Scientific. The offering will be limited to qualified institutional buyers and will utilize proceeds from the notes, along with other financing sources. This strategic move aims to enhance Avantor's capabilities in the life sciences sector. The notes will not be registered under the Securities Act, emphasizing their private nature.
Avantor, Inc. (NYSE: AVTR) reported preliminary unaudited revenues for Q3 2021, totaling $1.83 billion, a significant increase of 14.3% year-over-year, with organic growth at 10.2%. The company anticipates finalizing its Masterflex debt financing in Q4 2021. These preliminary results, reflecting management's current views, are subject to change prior to the official earnings release on October 29, 2021. The unaudited figures have not been reviewed by independent auditors and should not replace full financial statements.
Avantor, Inc. (NYSE: AVTR) will release its third quarter 2021 financial results on October 28, 2021, after market close. A conference call to discuss the results is scheduled for October 29, 2021, at 7:30 a.m. EDT. Interested parties can join by phone or listen to a live webcast via the investors section of our website. The earnings press release will be available on the company’s website.
Avantor announced the pricing of an underwritten offering of 20,833,334 shares of its common stock at $42.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 2,976,190 shares. Proceeds will primarily finance the acquisition of Masterflex from Antylia Scientific and may also support general corporate purposes. The offering is set to close on September 16, 2021, pending customary conditions. Goldman Sachs, Citigroup, and BofA Securities are among the joint book-running managers for this transaction.
Avantor announced plans to offer $750 million of common stock in an underwritten offering, related to a pending acquisition of the Masterflex bioprocessing business. The proceeds will also support debt financing. Underwriters may purchase additional shares within 30 days. The company aims to use net proceeds primarily for the acquisition, or for general corporate purposes if not completed. The offering's managers include Goldman Sachs, Citigroup, and BofA Securities.
Avantor, Inc. (NYSE: AVTR) announced a definitive agreement to acquire Masterflex bioprocessing business from Antylia Scientific for $2.9 billion, netting $2.7 billion after tax benefits. Masterflex, based in Illinois, focuses on peristaltic pumps and single-use fluid transfer technologies, generating approximately $300 million in estimated 2022 revenues. This acquisition aims to enhance Avantor's biopharma offerings, contributing to revenue growth and margin improvement. Completion is expected in Q4 2021, subject to regulatory approvals.
Avantor, Inc. (NYSE: AVTR) announced a multi-year investment to enhance its global hydration capabilities, completing a significant facility expansion in Gliwice, Poland, and initiating further expansion in Aurora, Ohio, projected to finish by mid-2022. This investment aims to support the biopharmaceutical industry's increasing demand for biologics by outsourcing buffer preparation, which can streamline workflows and accelerate therapy production. The expanded facilities will improve Avantor's ability to offer WFI-quality water buffer manufacturing, enhancing support for biopharma manufacturers globally.
Avantor, a global leader in mission-critical products for various industries, announced a virtual investor day scheduled for September 9, 2021, at 9:00 a.m. EDT. The event will be accessible via webcast on their official website, where a replay will also be available post-event. Avantor serves over 225,000 customer locations globally, impacting research and production across biopharma, healthcare, education, and advanced technology sectors. The company emphasizes forward-looking statements, cautioning that these may involve risks and uncertainties.
Avantor, Inc. (NYSE: AVTR) reported robust financial results for Q2 2021, with net sales of $1.86 billion, up 25.7% year-on-year. Net income surged 162.1% to $157.8 million. The company achieved 34.2% growth in Adjusted EBITDA to $366.6 million, with a margin expansion of 125 basis points. Despite two acquisitions, Ritter GMBH and RIM Bio, having no significant impact on quarterly results, the company raised its full-year guidance, reflecting confidence in ongoing momentum across various markets.